Access to HIV medication
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has repeatedly and clearly stated that patents must not prevent access from life-saving drugs for HIV patients living in resource limited settings. In line with this and in order to accelerate access to anti-retroviral medicines, the company has initiated non-assert declarations in May 2007, well before the idea of the UNITAID patent pool was conceived.
GSK expands presence in China through strategic cooperation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) have announced a cooperation agreement to form a long-term Joint Venture (JV) to develop and manufacture paediatric vaccines for use in China. The JV will produce vaccines for measles, mumps, and rubella (MMR) (Priorix™) and potentially other paediatric vaccines. GSK will also transfer the technology to enable the JV to manufacture the vaccines locally over time.
Sandoz launches somatropin, the first-ever Japanese biosimilar
- Details
- Category: Novartis
Sandoz announced the launch of its recombinant human growth hormone somatropin in Japan, the first-ever biosimilar to be approved and launched on the world's second largest pharmaceutical market.
Takeda to Establish Four Sales and Marketing Subsidiaries
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.
Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- Details
- Category: Novartis
Initial results from the two-year Phase III FREEDOMS study show that oral FTY720 (fingolimod) was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis (MS)[1] - one of the leading causes of neurological disability in young adults[3].
Merck Submits Application for Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).
The Lilly TB Drug Discovery Initiative Announces New Collaborator
- Details
- Category: Eli Lilly and Company
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs. The Lilly TB Drug Discovery Initiative's most important goal is filling the pipeline for faster, future TB drug development.
More Pharma News ...
- Abbott to Acquire Solvay Pharmaceuticals Business
- Novartis bronchodilator QAB149 recommended for approval in European Union
- Results from Abbott's PROSPECT Study Provide New Insight
- Herceptin provides impressive survival benefit for patients with high levels of HER2
- Results of ADAGIO study with Azilect® in Parkinson's disease published
- Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
- Analysis of BRAIN study shows that patients may have a stabilisation or improvement